Table 2 Histochemical study parameters results for PRGF group, Saline solution group and Control group (normal skeletal muscle) at 1 (T1), 2 (T2) and 4 (T4) weeks after treatment
Variable | Group | Group | Value (mean ± SD) |
|---|---|---|---|
Inflammatory cells density (cells/mm2) | T1 | PRGF | 47 ± 13(+,*) |
Saline solution | 87 ± 18(+,*) | ||
Control | 0 ± 0 | ||
T2 | PRGF | 52 ± 16(+,*) | |
Saline solution | 101 ± 40(+,*) | ||
Control | 0 ± 0 | ||
T4 | PRGF | 59 ± 16(+,*) | |
Saline solution | 107 ± 24(+,*) | ||
Control | 0 ± 0 | ||
Vascular area (µm2) | T1 | PRGF | 303 ± 77(+,*) |
Saline solution | 497 ± 127(+,*) | ||
Control | 40 ± 1 | ||
T2 | PRGF | 173 ± 25(+,*) | |
Saline solution | 373 ± 105(+,*) | ||
Control | 40 ± 2 | ||
T4 | PRGF | 160 ± 70(+) | |
Saline solution | 224 ± 96(+) | ||
Control | 39 ± 2 | ||
Vascular density (blood vessels/mm2) | T1 | PRGF | 21 ± 6(+) |
Saline solution | 26 ± 6(+) | ||
Control | 12 ± 2 | ||
T2 | PRGF | 16 ± 4(+) | |
Saline solution | 20 ± 4(+) | ||
Control | 10 ± 3 | ||
T4 | PRGF | 14 ± 3(+,*) | |
Saline solution | 20 ± 3(+,*) | ||
Control | 10 ± 2 | ||
Centrally nucleated fibers (%) | T1 | PRGF | 27 ± 5(+,*) |
Saline solution | 16 ± 5(+,*) | ||
Control | 0 ± 0 | ||
T2 | PRGF | 36 ± 11(+,*) | |
Saline solution | 25 ± 5(+,*) | ||
Control | 0 ± 0 | ||
T4 | PRGF | 50 ± 10(+,*) | |
Saline solution | 34 ± 6(+,*) | ||
Control | 0 ± 0 | ||
Fibrotic areas (%) | T1 | PRGF | 24 ± 3(+,*) |
Saline solution | 32 ± 5(+,*) | ||
Control | 0 ± 0 | ||
T2 | PRGF | 31 ± 5(+,*) | |
Saline solution | 42 ± 4(+,*) | ||
Control | 0 ± 0 | ||
T4 | PRGF | 22 ± 3(+,*) | |
Saline solution | 34 ± 5(+,*) | ||
Control | 0 ± 0 |